Brazil vs Kenya: HIV/AIDS deaths averted by antiretroviral therapy
Brazil
49,655 deaths
in 2024
Kenya
75,293 deaths
in 2024
Brazil rank
10th
Kenya rank
8th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Brazil
- Kenya
How they compare
Kenya currently reports 75,293 deaths against 49,655 deaths in Brazil, a difference of 25,638 deaths.
That makes Kenya's figure about 1.5 times Brazil's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Kenya ahead.
Brazil ranks 10th and Kenya ranks 8th of 157 countries.
Across the 4 decades both report, Brazil averaged higher in 1 and Kenya in 3.
Head to head by decade
| Decade | Brazil | Kenya | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 4,547 deaths | 0 deaths | 4,547 deaths | Brazil |
| 2000s | 15,777 deaths | 18,197 deaths | 2,421 deaths | Kenya |
| 2010s | 28,138 deaths | 71,552 deaths | 43,413 deaths | Kenya |
| 2020s | 47,798 deaths | 75,330 deaths | 27,532 deaths | Kenya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Brazil or Kenya?
- Kenya, at 75,293 deaths against 49,655 deaths in Brazil as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Brazil and Kenya?
- 25,638 deaths, with Kenya ahead.
- How many years of comparable data are there for Brazil and Kenya?
- 35 years are reported by both, from 1990 to 2024.
- How do Brazil and Kenya rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Brazil ranks 10th and Kenya ranks 8th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.